Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is leveraging its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time, potentially curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: hematology, immunology & oncology, liver and lung. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. For more information, please visit www.primemedicine.com . Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives. Position Overview We are seeking a motivated, experienced, and collaborative scientific/technical leader to drive the development of analytical and QC-ready methods for lipid nanoparticle (LNP) formulated Prime Editor drug products (DP). Working as a member of a highly collaborative Technical Development / CMC organization, this individual will contribute to strategy and hands-on execution of method development to enable stage-appropriate development from early formulation/process development through clinical development stages, leveraging platform approaches when possible. This is a scientific leadership and hands-on role. The successful candidate will be responsible for developing, qualifying, and validating analytical methods for DP release and stability testing, as well as in-process control and characterization. The ideal candidate has a strong chemistry background (particularly lipids and lipid excipients), deep expertise in chromatography and LC-MS, and experience with LNP biophysical characterization (e.g., DLS), and stays abreast of innovations in the field for these and other techniques. Excellent communication skills—especially technical writing, including authoring analytical sections of regulatory submissions and responding to regulatory questions—are strongly preferred. Bioanalysis experience supporting preclinical studies using LC-MS is a plus.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Education Level
Ph.D. or professional degree